Literature DB >> 12700245

Microorganisms and cancer: quest for a therapy.

A M Chakrabarty1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12700245      PMCID: PMC154404          DOI: 10.1128/JB.185.9.2683-2686.2003

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


× No keyword cloud information.
  38 in total

1.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

2.  The genome of the natural genetic engineer Agrobacterium tumefaciens C58.

Authors:  D W Wood; J C Setubal; R Kaul; D E Monks; J P Kitajima; V K Okura; Y Zhou; L Chen; G E Wood; N F Almeida; L Woo; Y Chen; I T Paulsen; J A Eisen; P D Karp; D Bovee; P Chapman; J Clendenning; G Deatherage; W Gillet; C Grant; T Kutyavin; R Levy; M J Li; E McClelland; A Palmieri; C Raymond; G Rouse; C Saenphimmachak; Z Wu; P Romero; D Gordon; S Zhang; H Yoo; Y Tao; P Biddle; M Jung; W Krespan; M Perry; B Gordon-Kamm; L Liao; S Kim; C Hendrick; Z Y Zhao; M Dolan; F Chumley; S V Tingey; J F Tomb; M P Gordon; M V Olson; E W Nester
Journal:  Science       Date:  2001-12-14       Impact factor: 47.728

3.  Can engineered bacteria help control cancer?

Authors:  R K Jain; N S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Combination bacteriolytic therapy for the treatment of experimental tumors.

Authors:  L H Dang; C Bettegowda; D L Huso; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-27       Impact factor: 11.205

5.  The bacterial redox protein azurin induces apoptosis in J774 macrophages through complex formation and stabilization of the tumor suppressor protein p53.

Authors:  Tohru Yamada; Masatoshi Goto; Vasu Punj; Olga Zaborina; Kazuhide Kimbara; T K Das Gupta; A M Chakrabarty
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Gene delivery by attenuated Salmonella typhimurium: comparing the efficacy of helper versus cytotoxic T cell priming in tumor vaccination.

Authors:  R Weth; O Christ; S Stevanovic; M Zöller
Journal:  Cancer Gene Ther       Date:  2001-08       Impact factor: 5.987

7.  Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia.

Authors:  M E Fox; M J Lemmon; M L Mauchline; T O Davis; A J Giaccia; N P Minton; J M Brown
Journal:  Gene Ther       Date:  1996-02       Impact factor: 5.250

8.  Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton.

Authors:  M Matsumoto; T Seya; S Kikkawa; S Tsuji; K Shida; M Nomura; M Kurita-Taniguchi; H Ohigashi; H Yokouchi; K Takami; A Hayashi; I Azuma; T Masaoka; K Kodama; K Toyoshima; M Higashiyama; H Takami
Journal:  Int Immunopharmacol       Date:  2001-08       Impact factor: 4.932

9.  NK cells are essential for effective BCG immunotherapy.

Authors:  S Brandau; J Riemensberger; M Jacobsen; D Kemp; W Zhao; X Zhao; D Jocham; T L Ratliff; A Böhle
Journal:  Int J Cancer       Date:  2001-06-01       Impact factor: 7.396

10.  Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis.

Authors:  C A Hunter; D Yu; M Gee; C V Ngo; C Sevignani; M Goldschmidt; T V Golovkina; S Evans; W F Lee; A Thomas-Tikhonenko
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

View more
  16 in total

Review 1.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

2.  Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo.

Authors:  Laura Masuelli; Fabrizio Pantanella; Giuseppe La Regina; Monica Benvenuto; Massimo Fantini; Rosanna Mattera; Enrica Di Stefano; Maurizio Mattei; Romano Silvestri; Serena Schippa; Vittorio Manzari; Andrea Modesti; Roberto Bei
Journal:  Tumour Biol       Date:  2015-10-13

3.  Leishmanial sphingolipid induces apoptosis in Sarcoma 180 cancer cells through regulation of tumour growth via angiogenic switchover.

Authors:  Subhadip Das; Nabanita Chatterjee; Dipayan Bose; Somenath Banerjee; Tarun Jha; Krishna Das Saha
Journal:  Tumour Biol       Date:  2014-12-19

Review 4.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

5.  Thermostable direct hemolysin downregulates human colon carcinoma cell proliferation with the involvement of E-cadherin, and β-catenin/Tcf-4 signaling.

Authors:  Pinki Chowdhury; Debasis Pore; Nibedita Mahata; Poulomee Karmakar; Amit Pal; Manoj K Chakrabarti
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

6.  Alternol inhibits proliferation and induces apoptosis in mouse lymphocyte leukemia (L1210) cells.

Authors:  Zhao-Zhe Liu; Jin Zhu; Bo Sun; Shu Liu; Shuo Geng; Xia Liu; Chang-Ling Li
Journal:  Mol Cell Biochem       Date:  2007-08-23       Impact factor: 3.396

7.  Bacteria under SOS evolve anticancer phenotypes.

Authors:  Shatha F Dallo; Tao Weitao
Journal:  Infect Agent Cancer       Date:  2010-02-05       Impact factor: 2.965

Review 8.  Immunotherapeutic advancements for glioblastoma.

Authors:  Leonel Ampie; Eric C Woolf; Christopher Dardis
Journal:  Front Oncol       Date:  2015-01-29       Impact factor: 6.244

9.  Challenges to Improve the Stability and Efficacy of an Intravesical BCG Product.

Authors:  Hamidreza Hozouri; Dariush Norouzian; Nastaran Nafissi-Varcheh; Reza Aboofazeli
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

Review 10.  Spontaneous regression of tumour and the role of microbial infection--possibilities for cancer treatment.

Authors:  Petra Kucerova; Monika Cervinkova
Journal:  Anticancer Drugs       Date:  2016-04       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.